Sugi Predict

Sugi Predict / Compounds / SCHEMBL4142891

SCHEMBL4142891

SCHEMBL4142891

N#Cc1ccc2c(c1)CCCC2N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 4/20 0.49
▸ CYP11B1 P15538 1/20 0.49
▸ KDM1A O60341 2/20 0.49
▸ LRRK2 Q5S007 6/20 0.43
▸ HTR6 P50406 1/20 0.42
▸ DPP4 P27487 1/20 0.41
▸ DRD2 P14416 2/20 0.40
▸ DRD3 P35462 2/20 0.40
▸ PNMT P11086 1/20 0.40
▸ PGR P06401 1/20 0.39
▸ NOS3 P29474 1/20 0.39
▸ NOS1 P29475 1/20 0.39
▸ NOS2 P35228 1/20 0.39
▸ CHRNA1 P02708 1/20 0.38
▸ CHRNG P07510 1/20 0.38
▸ CHRNB1 P11230 1/20 0.38
▸ CHRNB2 P17787 1/20 0.38
▸ CHRNB4 P30926 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4526621 1.00 CYP11B2 (0.49) CYP11B2CYP11B1KDM1ALRRK2HTR6
SCHEMBL31741085 1.00 CYP11B2 (0.49) CYP11B2CYP11B1KDM1ALRRK2HTR6
Hydrochloric Acid SCHEMBL30084207 0.98 CYP11B2 (0.48) CYP11B2CYP11B1KDM1ALRRK2HTR6
Hydrochloric Acid SCHEMBL30084163 0.98 CYP11B2 (0.48) CYP11B2CYP11B1KDM1ALRRK2HTR6
Hydrochloric Acid SCHEMBL5269175 0.98 CYP11B2 (0.48) CYP11B2CYP11B1KDM1ALRRK2HTR6
SCHEMBL3131162 0.90 KDM1A (0.44) CYP11B2CYP11B1KDM1ALRRK2DPP4
SCHEMBL4154608 0.90 KDM1A (0.44) CYP11B2CYP11B1KDM1ALRRK2DPP4
SCHEMBL8247897 0.90 KDM1A (0.44) CYP11B2CYP11B1KDM1ALRRK2DPP4
SCHEMBL29809032 0.90 KDM1A (0.44) CYP11B2CYP11B1KDM1ALRRK2DPP4
SCHEMBL30894874 0.90 KDM1A (0.44) CYP11B2CYP11B1KDM1ALRRK2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 — — US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 — — US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 — — US disclosed
WO-2022155419-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2022-07-21 — — WO disclosed
WO-2021178780-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2021-09-10 — — WO disclosed
WO-2021178780-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2021-09-10 — — WO disclosed
US-20090054460-A1 Piperazine derivatives and methods of use CHEN JIAN J 2009-02-26 — — US disclosed
US-20090048224-A1 COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2009-02-19 — — US disclosed
US-20090048224-A1 COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2009-02-19 — — US disclosed
US-7425631-B2 Compounds and methods of use AMGEN INC. (US) 2008-09-16 — — US disclosed
US-7199244-B2 Cyclic amine derivatives and methods of use AMGEN (US) 2007-04-03 — — US disclosed
EP-1656355-A2 PIPERAZINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2006-05-17 — — EP disclosed
WO-2006036664-A1 SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE AMGEN INC. (US) 2006-04-06 — — WO disclosed
EP-1633743-A1 CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ Amgen, Inc. (US) 2006-03-15 — — EP disclosed
EP-1631542-A1 BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF Amgen, Inc. (US) 2006-03-08 — — EP disclosed
WO-2005061467-A2 PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS AMGEN INC. (US) 2005-07-07 — — WO disclosed
US-20050124654-A1 Compounds and methods of use AMGEN INC. 2005-06-09 — — US disclosed
US-20050014749-A1 analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects AMGEN INC. 2005-01-20 — — US disclosed
WO-2004092116-A1 BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF AMGEN, INC. (US) 2004-10-28 — — WO disclosed
WO-2004092164-A1 CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ AMGEN, INC. (US) 2004-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124654-A1 Compounds and methods of use LTC4S, PTGES, LTB4R2 CYP11B2 22/4885CYP11B1 36/4885KDM1A 3729/4885
US-20090048224-A1 COMPOUNDS AND METHODS OF USE LTC4S, PTGES, LTB4R2 CYP11B2 22/4885CYP11B1 36/4885KDM1A 3729/4885
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS LRRK2, PARK7, GDI2 CYP11B2 1665/4885CYP11B1 1785/4885KDM1A 1182/4885
US-20090054460-A1 Piperazine derivatives and methods of use PTGES, PTGES2, PTGIS CYP11B2 118/4885CYP11B1 193/4885KDM1A 2901/4885
US-20050014749-A1 analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects ACHE, TNF, BCHE CYP11B2 553/4885CYP11B1 636/4885KDM1A 2555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.